Tempramed signs LOI for Panama distribution expansion

Executive Summary

• Tempramed Technologies Ltd. has signed a non-binding Letter of Intent (LOI) with TEM Consulting International S.A. to establish a distribution agreement for its VIVI product portfolio in Panama.
• The partnership marks a strategic expansion into Central America, leveraging TEM’s extensive nationwide reach across hospitals, clinics, and pharmacy networks.
• A definitive agreement is expected to be signed within 90 days, aiming to increase accessibility for temperature-regulated injectable medications in a market with rising prevalence of diabetes and obesity.

Key Details

• Parties Involved: Tempramed Technologies Ltd. (Seller/Manufacturer) and TEM Consulting International S.A. (Distributor).
• Agreement Type: Non-binding Letter of Intent (LOI) for a distribution agreement.
• Target Market: Panama, with plans to expand access to brick-and-mortar pharmacies, medical distributors, and medical-focused retail channels.
• Product Scope: Tempramed’s VIVI product portfolio, which includes temperature-regulated storage solutions for injectable medications (e.g., VIVI Cap, VIVI Cap Smart, VIVI Epi, VIVI Med).
• Timeline: The LOI is dated March 22, 2026, with a definitive agreement expected to be signed within 90 days.
• Strategic Context: This expands Tempramed’s global footprint, adding to existing partnerships in Korea, Turkey, Israel, and the Benelux regions.
• Market Rationale:
  • Diabetes: Panama has an estimated 312,800 adults (11.1% prevalence) with diabetes in 2024, projected to rise to 490,800 by 2050.
  • Obesity: Adult obesity prevalence is approximately 29.9%, with 73.9% combined overweight/obesity.
  • Payer Mix: Insulin is available via public system ($50–$160/month), while GLP-1 treatments are largely private-pay/out-of-pocket ($240–$400/month), targeting urban, higher-income patients.
• Distributor Capabilities: TEM specializes in import and distribution of surgical/medical disposables, with established relationships with major manufacturers (Dynarex, Medline, etc.) and access to Panama’s public and private health systems (Caja de Seguro Social, Ministerio de Salud).

Notable Quotes

• "We are thrilled this potential collaboration with TEM, whose deep expertise in health care logistics and omnichannel distribution aligns perfectly with our global growth strategy," said Ron Nagar, chief executive officer of Tempramed. "We are seeing significant demand and a growing need for the products we offer, especially in areas like Central America, where diabetes and obesity are on the rise. Having such partner in Central America marks an important step in our broader expansion globally. Together with TEM, we look forward to building a long-term partnership that will accelerate access to Tempramed's innovative solutions across America and beyond."